Statistics in Biopharmaceutical Research ( SBR), publishes articles that focus on the needs of researchers and applied statisticians in biopharmaceutical industries; academic biostatisticians from schools of medicine, veterinary medicine, public health, and pharmacy; statisticians and quantitative analysts working in regulatory agencies (e.g., U.S. Food and Drug Administration and its counterpart in other countries); statisticians with an interest in adopting methodology presented in this journal to their own fields; and nonstatisticians with an interest in applying statistical methods to biopharmaceutical problems.
Statistics in Biopharmaceutical Research accepts papers that discuss appropriate statistical methodology and information regarding the use of statistics in all phases of research, development, and practice in the pharmaceutical, biopharmaceutical, device, and diagnostics industries. Articles should focus on the development of novel statistical methods, novel applications of current methods, or the innovative application of statistical principles that can be used by statistical practitioners in these disciplines. Areas of application may include statistical methods for drug discovery, including papers that address issues of multiplicity, sequential trials, adaptive designs, etc.; preclinical and clinical studies; genomics and proteomics; bioassay; biomarkers and surrogate markers; models and analyses of drug history, including pharmacoeconomics, product life cycle, detection of adverse events in clinical studies, and postmarketing risk assessment; regulatory guidelines, including issues of standardization of terminology (e.g., CDISC), tolerance and specification limits related to pharmaceutical practice, and novel methods of drug approval; and detection of adverse events in clinical and toxicological studies. Tutorial articles also are welcome. Articles should include demonstrable evidence of the usefulness of this methodology (presumably by means of an application).
The Editorial Board of SBR intends to ensure that the journal continually provides important, useful, and timely information. To accomplish this, the board strives to attract outstanding articles by seeing that each submission receives a careful, thorough, and prompt review.

Editor
Frank Bretz 
Novartis 

Past Editor 
José Pinheiro 
Johnson & Johnson 
 
Editorial Coordinator
Jina Lee

Associate Editors
Stan Altan - Johnson & Johnson 
Björn Bornkamp - Novartis    
Gregory Campbell - U.S. Food and Drug Administration (retired) 
Aloka Chakravarty - U.S. Food and Drug Administration     
Ivan Chan - AbbVie Inc. 
Cong Chen - Merck 
Freda Cooner - Sanofi-Aventis 
Vladimir Dragalin - Johnson & Johnson 
Paul Gallo - Novartis 
Mithat Goenen - Memorial Sloan-Kettering Cancer Center 
Toshimitsu Hamasaki - National Cerebral and Cardiovascular Center 
Lisa Hampson - Novartis 
Weili He -Merck 
Antje Hoering - Cancer Research and Biostatistics 
Qi Jiang -Amgen Inc 
Franz Koenig - Medical University of Vienna 
Gregory Levin - U.S. Food and Drug Administration 
Sandeep Menon - Pfizer 
David Ohlssen - Novartis 
John O'Quigley - Universite Pierre et Marie Curie, Paris 6 
Brian Smith - Novartis 
An Vandebosch -Johnson & Johnson  
Xiaofei Wang – Duke University 
Yan (Daniel) Zhao - University of Oklahoma Health Sciences Center 

Journals Manager 
Eric Sampson